US Patent Number
Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin is employed in an anti-HIV vaccine. A process of producing the recombinant Tat protein includes steps for removing bacterial RNA from the recombinant Tat and for removing endotoxin from the recombinant Tat protein. A Tat-adsorbed nanoparticle formulation and method of making the same. A method of vaccinating against and/or treating HIV infection comprises administering to a subject in need of such vaccination or treatment an immune-response inducing effective amount of the recombinant Tat protein.
University of Kentucky Research Foundation, Lexington, KY (US)
Mumper, Russell J.; Woodward, Jerold; Cui, Zhengrong; and Nath, Avindra, "Compositions Comprising Human Immunodeficiency Virus Tat Adsorbed to the Surface of Anionic Nanoparticles" (2009). Pharmaceutical Sciences Faculty Patents. 123.